WallStSmart

Caribou Biosciences Inc (CRBU)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Caribou Biosciences Inc generates 1410% more annual revenue ($11.20M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

CRBU

Avoid

23

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -5.06

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CRBUUndervalued (+45.5%)

Margin of Safety

+45.5%

Fair Value

$2.92

Current Price

$1.92

$1.00 discount

UndervaluedFair: $2.92Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRBU2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CRBU4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.9%4/10

1.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$198.86M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CRBU

The strongest argument for CRBU centers on Debt/Equity, Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CRBU

The primary concerns for CRBU are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CRBU carries more volatility with a beta of 2.33 — expect wider price swings.

CRBU is growing revenue faster at 1.9% — sustainability is the question.

CRBU generates stronger free cash flow (-27M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 23/100). CRBU offers better value entry with a 45.5% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caribou Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in cutting-edge genome editing technologies, particularly through its proprietary CRISPR platform. With a robust and diversified pipeline of innovative product candidates aimed at tackling urgent unmet medical needs in genetic disorders and oncology, the company is well-positioned to lead advancements in precision medicine. Leveraging strategic partnerships and a commitment to transformative research, Caribou aims to redefine treatment paradigms and significantly improve patient outcomes, establishing itself as a formidable entity in the biopharmaceutical sector.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?